Call for Submissions
The Journal for ImmunoTherapy of Cancer (JITC) welcomes submissions in the following areas and related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
Clinical/Translational Cancer Immunotherapy
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Clinical Trials Monitor
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape.
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
Benefits of Publication
Open Access and No Copyright Transfer
Content freely available upon publication.
Articles published within 2-4 weeks of acceptance.
Featured in six major indexing resources including:
- PubMed Central
- The Directory of Open Access Journals
- Clarivate Analytics' Emerging Sources Citation Index
Stringent Ethical Standards
Published by BioMed Central, a member of the Committee on Publishing Ethics.
Complimentary Article Promotion
Monthly JITC Digest sent to global experts.
Eligibility for JITC Best Paper Awards
Recipients Receive $1,000* and recognition at SITC's Annual Meeting.
*Papers published between August 2016 to September 2017 authored by SITC members are eligible for nomination for awards. Papers on which the first or senior author is a SITC member are eligible for consideration. Join SITC, renew your membership, or check your current membership status.
Submit your Manuscript to JITC